drugset / Trial / NCT03389256
Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC
Phase 2
Unknown
144 enrolled
Sichuan Cancer Hospital and Research Institute
Jiangsu HengRui Medicine Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This phase 2 study is designed to evaluate the safety and activity of apatinib,a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2, in combination with EGFR-TKI in NSCLC with T790M-negative after the failure of EGFR-TKI therapy.
Timeline
- Start
- 2018-12-30
- Primary completion
- 2020-12-30
- Completion
- 2022-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | 500 mg | Oral |
| Background | Erlotinib | Small molecule | 150 mg | Oral |
| Background | Gefitinib | Small molecule | 250 mg | Oral |
| Background | Imatinib | Small molecule | 125 mg | Oral |